đŸ’„ Debunking the Lie: “The U.S. is 5% of the world’s population but consumes 80% of the world’s opioids and 99% of the world’s hydrocodone.”

Details
Hits: 1578

đŸ’„ Debunking the Lie: “The U.S. is 5% of the world’s population but consumes 80% of the world’s opioids and 99% of the world’s hydrocodone.”

For free printable resources, please go to our Patreon Page and subscribe (free)

⚠ TL;DR:

The claim that the U.S. consumes 80% of the world’s prescription opioids and 99% of its hydrocodone is outdated, misleading, and based on cherry-picked data from over a decade ago.

  • These stats do not reflect current U.S. prescribing practices, which have dropped dramatically since 2011.

  • Global opioid access is severely limited in low- and middle-income countries, skewing comparisons. Many countries can’t access opioids even for cancer pain.

  • The “99% of hydrocodone” stat is technically true for raw quantity, but it’s misleading—most countries don’t use hydrocodone at all. The U.S. did prescribe it widely because of FDA classification and prescribing preferences.

  • Repeating this stat without context has been used to justify dangerous policies, vilify pain patients and prescribers, and ignore the real issue: inequitable global access to pain relief.

📚 Table of Contents

1. Where Did This Stat Come From?

The statement that “the U.S. is 5% of the world’s population but consumes 80% of the world’s opioids and 99% of its hydrocodone” has been repeated in media, academic journals, legislative hearings, and even Supreme Court testimony. But it’s not current, not contextualized, and not the full story.

The Numbers Came From an INCB Report — Over a Decade Ago

This statistic traces back to a 2011 report by the International Narcotics Control Board (INCB). The report reviewed 2010 global opioid consumption and stated:

“The United States of America accounted for 99.1 per cent of the consumption of hydrocodone. The country also accounted for 83.1 per cent of the consumption of oxycodone.”
— INCB Technical Report 2011, p. 119
https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2011/Part_FOUR_Comments_NAR-Report-2011_English.pdf

This reflected a period when U.S. opioid prescribing was at its peak — before the CDC guidelines, before the DEA crackdowns, and before widespread PDMP surveillance. But the stat has been frozen in time and repeated long after the data stopped being relevant.

📣 Who Repeated It?

After 2011, the stat took on a life of its own. It was used by:

  • Public health officials to justify prescribing restrictions

  • PROP-affiliated activists to promote opioid reduction

  • Media outlets and government agencies to sensationalize the crisis

  • Plaintiffs in the opioid multidistrict litigation (MDL) to show “overprescribing” and corporate excess

A 2018 article in Pain News Network traced the spread of the stat and how it’s often misrepresented:

“Like many statistics, the 80% claim has a kernel of truth, but lacks context and is being used to support a false narrative.”
— Pat Anson, Pain News Network (2018)

💊 Hydrocodone Was Mostly an American Drug

The “99% of hydrocodone” figure is technically true — but it’s also misleading. It doesn’t mean Americans were more addicted or irresponsible. It means:

  • The U.S. favored hydrocodone over other opioids for decades

  • Hydrocodone was Schedule III until 2014, making it easier to prescribe than oxycodone

  • Most countries don’t even use hydrocodone — they rely on morphine, tramadol, or codeine

“Hydrocodone has long been the most prescribed drug in the United States. In 2012, doctors wrote 135 million prescriptions.”
— Drug Topics, 2014
https://www.drugtopics.com/view/hydrocodone-question

⚖ A Stat Built for Blame — and Lawsuits

This framing didn’t just happen by accident. It served the opioid litigation narrative perfectly:

  • It made the U.S. look like the epicenter of a corporate-fueled disaster

  • It gave lawyers and policymakers a way to blame volume instead of context

  • It helped secure massive opioid settlements by depicting American prescribing as uniquely excessive

Instead of pushing for better global access to pain relief, the stat was used to justify:

  • PDMP crackdowns

  • Forced tapers

  • Doctor prosecutions

  • Surveillance of stable pain patients

It became a weapon against care, not a call for equity.

🧠 What Was Left Out

What this stat never acknowledged is the global pain divide. Most of the world doesn’t have access to basic pain relief:

  • According to the INCB, 89% of global morphine is consumed by the richest 10% of countries

  • In many countries, cancer patients die in agony due to lack of access to opioids

  • Low- and middle-income countries are drastically under-supplied — not because of caution, but because of poverty, stigma, and international restrictions

By comparing the U.S. to countries with no access, the stat manufactures excess by erasing global inequality.

2. U.S. Opioid Prescribing Has Plummeted

Even if the U.S. once led the world in opioid prescribing, that is no longer the case. Since its peak around 2011–2012, prescription opioid volume has dropped dramatically, both in total prescriptions and in morphine milligram equivalents (MME).

Yet the old “80% of the world’s opioids” stat continues to circulate—as if nothing has changed.

📉 By the Numbers: A Decade of Decline

  • According to IQVIA Institute (2022), the U.S. saw a 60% drop in total opioid prescribing volume (by MME) from its 2011 peak.
    📎 Source: IQVIA Opioid Trends Report

  • The CDC reported over 255 million prescriptions in 2012, compared to around 125 million in 2023—more than a 50% drop in prescriptions dispensed.

  • The average MME per capita has decreased year after year, and prescribing thresholds are now embedded in PDMPs, insurance rules, and even legal prosecutions.

According to the IQVIA Institute, total national prescription opioid use has declined by 60% from its peak in 2011. Meanwhile, the CDC reported 107,941 drug overdose deaths in 2022, highlighting that overdose deaths have continued to rise.

  • IQVIA Institute Report: Prescription Opioid Trends in the United States
    This report indicates that prescription opioid volume is expected to drop for the ninth consecutive year—a decline of 60% from its peak in 2011.
    📎 Read the full report​

  • CDC Data Brief: Drug Overdose Deaths in the United States, 2002–2022
    This brief reports that in 2022, 107,941 drug overdose deaths occurred, resulting in an age-adjusted rate of 32.6 deaths per 100,000 standard population.
    📎 Access the data brief

📉 Hydrocodone Use Has Collapsed

  • Hydrocodone was once the most prescribed drug in the U.S.

  • After it was rescheduled from Schedule III to Schedule II in 2014, prescribing plummeted.

  • The U.S. still leads in hydrocodone use—but the total volume has dropped drastically.

This is crucial because the 99% hydrocodone stat is still repeated as if nothing changed, even though usage has been curtailed by:

  • Scheduling changes

  • Insurance limitations

  • NarxCare risk flags

  • Practitioner fear of regulatory scrutiny

📉 Doctors Are Prescribing Less Than Ever—But Facing More Punishment

Despite the massive reduction in opioid prescribing:

  • Overdose deaths have increased, driven by illicit fentanyl, not pain medications.

  • Doctors are still being prosecuted, patients still cut off, and outdated consumption stats are still used in courtrooms and news stories to justify policies based on volume—not reality.

Pain patients, meanwhile, are left untreated or abandoned—while anti-opioid advocates continue to cite decade-old consumption stats to defend surveillance and restrictions.

🔍 Why This Matters

Repeating the “80% of the world’s opioids” claim today is like saying:

“The U.S. leads the world in flip phone sales.”

It was once technically true, but the world has changed—and the policies built on that outdated narrative are still hurting people today.

3. Global Access to Pain Relief is Deeply Unequal

The claim that “America consumes the vast majority of the world’s opioids” implies overuse—but that’s only true if everyone else has equal access.

They don’t.

The real story isn’t that the U.S. uses “too many” opioids. It’s that most of the world uses almost none—even for devastating conditions like cancer or end-of-life pain. That’s not excess. It’s inequality.

🌐 Most Countries Can’t Access Basic Pain Relief

According to the 2017 Lancet Commission on Palliative Care and Pain Relief, over 61 million people globally suffer each year without access to adequate pain relief. Nearly 83% of the world’s population consumes just 10% of the morphine distributed worldwide.

“The poorest 50% of the world’s population receives only 1% of the morphine distributed.”
— Lancet Commission, 2017
Source

These disparities are driven by:

  • Fear of opioid misuse and international pressure to restrict use

  • Lack of training in pain management

  • Government refusal to stock opioids in public hospitals

  • Onerous import regulations and licensing rules

In many countries, morphine is legally available but practically inaccessible—and patients with advanced cancer are often left to suffer.

📊 INCB Data Confirms Global Inequality

The International Narcotics Control Board (INCB) has acknowledged this disparity for years. Their 2020 technical report confirms:

“There is a stark contrast in the availability of opioid analgesics between high-income and low-income countries.”
— INCB Technical Report, 2020
Source PDF

For example:

  • The United States and Canada consume the bulk of medical-grade morphine, oxycodone, and hydromorphone.

  • Many countries across Africa, Asia, and Latin America receive so little morphine that their entire annual supply wouldn't be enough for a single large U.S. hospital.

đŸ€Ż When Low Access Gets Used to Manufacture "Overuse"

The narrative that the U.S. uses “most of the world’s opioids” only holds up if you:

  • Ignore the fact that most countries can’t access opioids

  • Treat absence of pain treatment as the norm

  • Frame pain relief as a luxury, not a human right

In reality, America’s “large share” of opioid consumption says more about how little the rest of the world has than about how much the U.S. uses.

Pain is global. Access to pain relief should be too.

4. The Truth About Hydrocodone Use

The claim that the U.S. consumes “99% of the world’s hydrocodone” is often used as a rhetorical hammer to suggest reckless overuse. But like the “80% of opioids” stat, it leaves out critical context that completely changes its meaning.

✅ Yes, the U.S. Consumed Nearly All Hydrocodone — But There’s a Reason

The INCB 2011 report stated that the United States accounted for 99.1% of global hydrocodone consumption in 2010. INCB Report, 2011 – Page 119


But here’s what that stat doesn’t explain:

  • Most countries don’t prescribe hydrocodone at all.
    It was never adopted as a first-line analgesic outside the U.S.

  • The U.S. preferred hydrocodone due to drug scheduling.
    Until 2014, hydrocodone combination products (e.g., Vicodin) were Schedule III, making them easier to prescribe than oxycodone (Schedule II). This incentivized overreliance in primary care.

  • Hydrocodone was used primarily in combination pills.
    Many other countries prescribe plain morphine or codeine instead.

So yes, the U.S. used the vast majority of hydrocodone — not because Americans overused opioids, but because hydrocodone was an American regulatory oddity.

“Hydrocodone has long been the most prescribed drug in the United States. In 2012, doctors wrote 135 million prescriptions for it.”
— Drug Topics (2014)
Source

📉 What Happened After It Was Rescheduled?

In 2014, the DEA reclassified hydrocodone combo products as Schedule II, aligning it with oxycodone in terms of restrictions. The results were immediate:

  • Hydrocodone prescribing plummeted

  • Doctors turned to alternative treatments or stopped prescribing opioids altogether

  • Many pain patients faced new barriers to access and stricter refill limits

Despite this, the “99%” stat is still repeated in articles, testimony, and medical education — without mentioning that use has dropped dramatically in the decade since.

đŸ€” Why the Stat Persists

Because it sounds damning. It works as a headline. It plays into the idea that the U.S. is uniquely irresponsible with opioids. But it only works if you:

  • Ignore scheduling laws

  • Ignore global prescribing norms

  • Ignore that prescribing patterns have since changed

And most of all, it only works if you want to weaponize volume without explaining why that volume existed in the first place.

5. The Harm of Using This Myth in Policy

The claim that the U.S. consumes 80% of the world’s opioids and 99% of its hydrocodone didn’t just shape opinions — it shaped laws, medical practice, surveillance systems, and courtroom outcomes.

What started as a flawed data point became a policy weapon, used to justify restriction, criminalization, and abandonment of people in pain.

📉 It Fueled the CDC’s 2016 Guidelines

The CDC’s 2016 opioid prescribing guideline — now widely recognized as harmful and misapplied — was introduced in a climate dominated by volume-based rhetoric. Policymakers and media emphasized the “America uses 80%” stat as evidence that doctors were overprescribing, and patients were overusing.

That narrative:

  • Ignored global under-treatment of pain

  • Dismissed patients with legitimate chronic conditions

  • Justified dose thresholds, prescription limits, and blunt surveillance tools like PDMPs and NarxCare

⚖ It Strengthened the Opioid Litigation Narrative

In the opioid multidistrict litigation (MDL), attorneys for states and municipalities needed to show excess, damage, and corporate irresponsibility. The “80%” and “99%” stats were perfectly suited for this.

They helped establish:

  • A public image of “pill flooding”

  • A villainous narrative of American overconsumption

  • A simplified version of the crisis that ignored fentanyl, poverty, trauma, and policy failure

This narrative brought in billions in settlement funds — but did little to improve pain care or provide nuanced solutions.

🧠 It Justified Abandonment, Surveillance, and Tapering

Once policymakers accepted the premise that “America uses too many opioids,” it became easy to:

  • Flag high-dose patients as outliers, regardless of individual need

  • Force tapers under the assumption that opioid use = addiction

  • Criminalize prescribers simply for operating above an arbitrary MME threshold

  • Deny surgeries, refills, and care access to people flagged in NarxCare or PDMP systems

All of this was fueled by the belief that volume equals wrongdoing.

If America was using 80% of the world’s opioids, someone had to be blamed.

And instead of looking at systemic inequality in global access, the blame fell squarely on:

  • Pain patients

  • Primary care doctors

  • Palliative and hospice clinicians

  • Rural and underserved communities

🔁 The Lie Has Outlived the Reality

U.S. prescribing has dropped by over 60%.
Hydrocodone has been rescheduled.
Deaths are now driven by illicit fentanyl, not prescription pills.

And yet — this myth is still being repeated in:

  • Public health campaigns

  • Opioid prescriber education

  • Addiction treatment literature

  • Testimony and policy proposals

It’s used to shame, restrict, and surveil — not to help.

6. What the Data Really Shows

The idea that the U.S. “uses most of the world’s opioids” makes for a good headline — but the data tells a different story.

Today, opioid prescribing in the U.S. has dropped dramatically, while most of the world still faces crippling under-access to basic pain relief. The result is a misleading picture that frames inequality as overuse.

Let’s set the record straight.

📉 U.S. Opioid Prescribing Has Fallen — A Lot

  • According to the IQVIA Institute (2022), total prescription opioid volume in the U.S. dropped by 60% since its 2011 peak.
    📎 IQVIA Report

  • CDC data confirms that opioid prescribing peaked at 255 million prescriptions in 2012, and dropped to ~125 million by 2023 — a 50%+ reduction in volume.

  • The U.S. now prescribes fewer opioids per capita than it did in the early 2000s — yet myth-based policies persist as if nothing has changed.

🌍 Most of the World Still Can’t Access Pain Relief

From the Lancet Commission on Palliative Care and Pain Relief (2017):

“The poorest 50% of the world’s population receives only 1% of the morphine distributed globally.”
📎 Lancet Source

And from the INCB Technical Report (2020):

“There is a stark contrast in the availability of opioid analgesics between high-income and low-income countries.”
📎 INCB Report PDF

Despite legitimate need, many countries:

  • Restrict or ban opioids outright

  • Lack trained providers

  • Face crushing import/export regulations

  • Fear international penalties for “overuse”

This is why opioid consumption data skews so heavily toward the U.S. and a handful of wealthy countries — not because those countries overprescribe, but because most others can't prescribe at all.

📊 What the INCB Actually Reports

The INCB provides annual narcotic drug consumption statistics. Here’s what they show:

  • The U.S. still consumes more morphine and oxycodone than most countries — but so do Canada, Germany, Australia, and the UK.

  • High-income countries consistently represent the vast majority of total opioid use — not because of abuse, but because of access.

In short: The U.S. consumes a large share because it can. That doesn’t mean it’s abusing the system. It means the system is failing most of the world.

🧠 The Real Takeaway

Opioid consumption numbers don’t tell us who’s overusing.
They tell us who can access relief — and who can’t.

Framing this as a story of American excess erases global suffering and has been used to punish pain patients instead of solving disparities.

The real public health question isn’t “Why does the U.S. consume so much?”
It’s “Why can’t the rest of the world access what they need?”

7. Call to Action

The myth that “America is 5% of the world’s population but consumes 80% of the world’s opioids and 99% of its hydrocodone” has been used for over a decade to shame doctors, punish pain patients, and drive one-size-fits-all policies rooted in volume — not context.

But the truth is clear:

  • The U.S. no longer leads the world in opioid prescribing per capita the way it once did.

  • Prescribing has dropped by more than half, while overdose deaths (driven by illicit fentanyl) have surged.

  • The so-called “overuse” is mostly a reflection of the rest of the world’s inaccessibility to pain relief, not excess in the U.S.

It’s time to retire this myth — and the policies built on it.

What You Can Do:

✅ Stop Repeating the Stat
Whether you're a policymaker, public health leader, journalist, or educator: don’t repeat the “80%” or “99%” claim without context. It’s outdated, misleading, and harmful.

✅ Correct the Record
Push back when this myth is used in hearings, academic papers, litigation narratives, or opioid guidelines. Use verified sources like the INCB, IQVIA, and The Lancet.

✅ Push for Global Access — Not Global Restriction
We don’t need fewer opioids in the U.S. — we need better, safer, more compassionate access to pain care worldwide.

✅ Support Balanced Policies
Pain patients shouldn’t be punished to make numbers look better on a chart. Policies should reflect individual needs, not arbitrary national consumption stats.

✅ Educate with Facts, Not Fear
If you advocate for addiction treatment, don’t do it at the expense of pain patients. Don’t use weaponized stats to win funding or political leverage. We can solve multiple problems without sacrificing people who are suffering.

Final Thought

Pain isn’t a luxury.
Opioid access isn’t proof of abuse.
And using distorted global stats to justify local harm isn’t public health.

Let’s stop using this myth to build bad policy — and start building systems that care for everyone in pain, everywhere in the world.

Citations

For free printable resources, please go to our Patreon Page and subscribe (free)

The Doctor Patient Forum

Claudia A. Merandi 5 Chedell Ave, E Providence, RI 029141.401.523.0426

Follow Us: PATREON SPOTIFY FACEBOOK  YOU TUBE TIK TOK 2 TWITTER